The Role of HER2 Status in the Biliary Tract Cancers

被引：8
|
作者：
Ayasun, Ruveyda [1 ]
Ozer, Muhammet [2 ]
Sahin, Ilyas [3 ]
机构：
[1] NYU, Laura & Isaac Perlmutter Canc Ctr, Langone Med Ctr, New York, NY 10016 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02132 USA
[3] Univ Florida Hlth Canc Ctr, Dept Med, Div Hematol Oncol, Gainesville, FL 32608 USA
来源：
CANCERS | 2023年 / 15卷 / 09期
关键词：
biliary tract cancer; HER2; status; precision medicine; DABRAFENIB PLUS TRAMETINIB; OPEN-LABEL; METASTATIC CHOLANGIOCARCINOMA; SINGLE-ARM; MULTICENTER; THERAPIES; PHASE-2; GEMCITABINE; FUTIBATINIB; MECHANISMS;
D O I：
10.3390/cancers15092628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Despite recent advances, biliary tract cancer (BTC) is traditionally known as being hard to treat with a poor prognosis. Recent state-of-the-art genomic technologies such as next-generation sequencing (NGS) revolutionized cancer management and shed light on the genomic landscape of BTCs. There are ongoing clinical trials to assess the efficacy of HER2-blocking antibodies or drug conjugates in BTCs with HER2 amplifications. However, HER2 amplifications may not be the sole eligibility factor for these clinical trials. In this review, we aimed to comprehensively examine the role of somatic HER2 alterations and amplifications in patient stratification and provide an overview of the current state of ongoing clinical trials.
引用
收藏
页数：12
相关论文
共 50 条
  • [41] Immunotherapy in Biliary Tract Cancers: Current Standard-of-Care and Emerging Strategies
    Lo, Justin H. H.
    Agarwal, Rajiv
    Goff, Laura W. W.
    Heumann, Thatcher R. R.
    CANCERS, 2023, 15 (13)
  • [42] Fibroblast growth factor therapies in biliary tract cancers: current and future state
    Siripoon, Teerada
    O'Donnell, Conor
    Jin, Zhaohui
    Mahipal, Amit
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2024, 33 (12) : 1245 - 1255
  • [43] Automatization of HER2 Status Assessment in Breast Cancer
    Makhov, Denis
    Samorodov, Andrey
    Slavnova, Elena
    2019 URAL SYMPOSIUM ON BIOMEDICAL ENGINEERING, RADIOELECTRONICS AND INFORMATION TECHNOLOGY (USBEREIT), 2019, : 171 - 173
  • [44] Biliary tract cancers: systemic therapy for advanced disease
    Martinez, Francisco J.
    Shroff, Rachna T.
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (01)
  • [45] Adjuvant therapy of biliary tract cancers
    Kefas, Joanna
    Bridgewater, John
    Vogel, Arndt
    Stein, Alexander
    Primrose, John
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [46] Gemcitabine in advanced biliary tract cancers
    Pasetto, Lara Maria
    Andrea, Mario Rosario D'
    Falci, Cristina
    Monfardini, Silvio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2007, 61 (03) : 230 - 242
  • [47] Current status of HER2 testing
    Di Leo, A
    Dowsett, M
    Horten, B
    Penault-Llorca, F
    ONCOLOGY, 2002, 63 : 25 - 32
  • [48] The status of HER2 in colorectal carcinoma and the relation of HER2 with prognostic parameters and MSI
    Saygin, Ismail
    Cakir, Emel
    INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2022, 65 (02) : 336 - 342
  • [49] An ODE Model for the HER2/3-AKT Signaling Pathway in Cancers that Overexpress HER2
    Itani, Solomon
    Gray, Joe
    Tomlin, Claire J.
    2010 AMERICAN CONTROL CONFERENCE, 2010, : 1235 - 1241
  • [50] The Bioinformatics Analysis of miRNAs Signatures Differentially Expressed in HER2(+) Versus HER2(-) Breast Cancers
    Nie, Weiwei
    Jin, Lei
    Wang, Yanru
    Wang, Zexing
    Guan, Xiaoxiang
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2013, 28 (01) : 71 - 76
12345